[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
[3] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[4] |
FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe.
Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
|
[5] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[6] |
LI Xingren, SHEN Aizong, SU Dan.
Evaluation of the rationality of proton pump inhibitors in preventing perioperative stress related mucosal disease in biliary and pancreatic surgery
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1022-1026.
|
[7] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[8] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[9] |
CHEN Jie, QIN Kan.
Evaluation of individualized parenteral nutrition delivery
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816.
|
[10] |
LIU Jing, XIA Liang, ZHANG Shijie.
Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
|
[11] |
NIE Xiaolu, TANG Shaowen, YU Jinyang, SONG Haibo, FU Zhu, SUN Feng.
Interpretations of reporting recommendations intended for pharmaceutical risk minimization evaluation studies(RIMES) statement
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 524-529.
|
[12] |
YUE Xiaolin, LU Song, ZHANG Lan.
Research in the construction of comprehensive evaluation systems of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
|
[13] |
LIU Huan, YUAN Hui, YIN Jingjing, LIU Mengya, QIN Xiujun, LI Jianguo.
General toxicology of Yiya Jianpi jel among juvenile animals
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 416-422.
|
[14] |
LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng.
Quality analysis of Guci tablets based on national drug evaluation sampling
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
|
[15] |
WANG Yadan, YAN Jiangong, CHEN Minghui, PANG Yu, DAI Zhong, MA Shuangcheng.
UPLC fingerprints of tripterygium glycosides tablets from different manufacturers
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 146-151.
|